Rare / Orphan Disease
🧠

Spinal Muscular Atrophy (SMA)

Spinal muscular atrophy (SMA) is a rare inherited neuromuscular disease caused by mutations in the SMN1 gene, leading to progressive muscle weakness and loss of motor function. Three FDA-approved disease-modifying therapies now exist — including Zolgensma, the world's most expensive drug.

SMA affects approximately 25,000 Americans and is the #1 genetic cause of infant death. All 50 U.S. states now screen for SMA at birth — children treated before symptoms appear often achieve near-normal motor development.

📡 NIH · CDC · FDA · ClinicalTrials.gov 🔔 Get Alerts
📊 SMA by the Numbers
25K
Americans living with SMA
1 in 6,000
live births affected
3
FDA-approved disease-modifying therapies
2.1M
Zolgensma list price ($) — most expensive drug ever
🔄 Myth vs. Fact
❌ Myth

"SMA is always fatal in infancy."

👆 Tap to see the truth

✅ Fact

With newborn screening and early treatment, children diagnosed before symptoms appear can achieve near-normal motor development. The earlier the treatment, the better the outcome.

👆 Tap to flip back

❌ Myth

"SMA only affects children."

👆 Tap to see the truth

✅ Fact

SMA types 2, 3, and 4 can first present in teens and adults. Adult-onset SMA (type 4) is often diagnosed late and confused with other neuromuscular diseases.

👆 Tap to flip back

❌ Myth

"There's only one type of SMA."

👆 Tap to see the truth

✅ Fact

SMA has 5 types (0–4) classified by age of onset and highest motor function achieved. All are caused by SMN1 gene mutations, but prognosis and treatment response differ significantly.

👆 Tap to flip back

❌ Myth

"Gene therapy is only for newborns."

👆 Tap to see the truth

✅ Fact

Spinraza (nusinersen) and Evrysdi (risdiplam) are approved for all ages. Zolgensma (gene therapy) is approved for children under 2, but older patients can still benefit from the other therapies.

👆 Tap to flip back

Did You Know?
SMA is now included in newborn screening in all 50 U.S. states — meaning most new cases are diagnosed before symptoms appear.
Zolgensma ($2.1M) is the most expensive drug ever approved — but Novartis offers outcome-based payment models and a compassionate use lottery in some countries.
Evrysdi is the only oral treatment for SMA — a game-changer for patients who previously required intrathecal injections or IV infusions.
SMA was the #1 genetic cause of infant death before 2016. Spinraza approval that year marked the first disease-modifying therapy for any neurodegenerative disease in children.
The SMN2 gene acts as a 'backup copy' — more SMN2 copies generally means milder SMA. All three approved therapies work by increasing SMN protein from SMN2.
🍩 Breakdown by Type
60% Type
60% Type 1 (infantile-onset)
27% Type 2 (intermediate)
13% Types 3–4 (late-onset)
📅 Disease Progression
Day 0–5 (via heel stick)
Newborn Screening
All 50 states screen for SMA. Early identification — before motor neurons are lost — produces the best outcomes. Pre-symptomatic treatment is the goal.
Days 1–30 post-diagnosis
Treatment Decision
For infants: Zolgensma (one-time gene therapy, <2 years old) vs. Spinraza (intrathecal injections) vs. Evrysdi (oral). Insurance and access factors heavily.
Months 1–12
Early Therapy Response
Pre-symptomatic infants treated with Zolgensma or Spinraza show near-normal motor milestone achievement in clinical trials. Ongoing monitoring.
Life-long
Long-term Management
Pulmonology, orthopedics, nutrition, PT/OT. Respiratory support critical in types 1–2. Adults with type 3–4: occupational independence, employment, fertility.

"SMA is now screened at birth in all 50 states — and treated children can grow up with near-normal motor function."

💊 FDA-Approved Treatments for SMA

There are currently 3 FDA-approved disease-modifying therapies for SMA. These are targeted treatments — not just symptom management.

FDA Approved 2019

Zolgensma

onasemnogene abeparvovec-xioi

Company Novartis / AveXis
Drug type Gene Therapy (one-time)
Approved for SMA in children under 2 years of age
List price ~$2,100,000 (one-time)

💚 Financial Assistance Available

Novartis offers outcomes-based payment model and financial assistance programs. AveXis patient services navigate insurance access. Medicaid covers Zolgensma in most states. If it works, you pay; if not, you get money back.

FDA Approved 2016

Spinraza

nusinersen

Company Biogen
Drug type Antisense Oligonucleotide
Approved for SMA in patients of all ages and all types
List price ~$750,000/year (first year), ~$375,000/year (maintenance)

💚 Financial Assistance Available

Biogen SMA 360 support program provides co-pay assistance and outcomes-based agreements with major insurers. First FDA-approved SMA therapy — intrathecal (spinal) injection every 4 months after loading.

FDA Approved 2020

Evrysdi

risdiplam

Company Roche / Genentech
Drug type Small Molecule Oral
Approved for SMA in patients 2 months and older (all types)
List price ~$340,000/year

💚 Financial Assistance Available

Genentech Access Solutions provides co-pay assistance and free drug programs. Only oral SMA therapy — taken as a liquid daily. Often preferred for older children and adults who want to avoid injections.

⚠️ High-cost drugs: insurance navigation matters

These treatments require prior authorization from your insurer. Most commercial insurance plans cover them with co-pay assistance programs. Medicare and Medicaid coverage varies by state and therapy. Ask your specialist's office for a patient navigator or specialty pharmacy partner — they handle PA processes daily.

SMA diagnosis: what you need to know and do right now.

A diagnosis can feel overwhelming. Here's what patients and specialists say makes the biggest difference in the weeks after diagnosis.

⚡
1

Time matters — early treatment produces the best outcomes

For infants, motor neurons lost before treatment begins cannot be recovered. Pre-symptomatic treatment (found via newborn screening before symptoms appear) consistently produces the best results. If your child was just diagnosed, request urgent specialist referral and treatment discussion immediately.

👨‍⚕️
2

See a neuromuscular specialist with SMA experience

SMA is rare and treatment decisions are complex. Seek a pediatric neurologist (for children) or adult neurologist with neuromuscular expertise. Large academic medical centers and children's hospitals have dedicated SMA teams. The SMA Foundation (smafoundation.org) maintains a care center directory.

💊
3

Understand the three treatment options

Zolgensma (gene therapy, one-time, <2 years old), Spinraza (intrathecal injections, all ages), and Evrysdi (oral daily, 2 months+) are all approved. Zolgensma is the best option for eligible infants due to its one-time administration. For older patients, Spinraza and Evrysdi both improve function — Evrysdi's oral route often makes it the preferred choice for older children and adults.

💰
4

Cost assistance is available — don't let price deter you

Zolgensma ($2.1M) has multiple access pathways: commercial insurance typically covers it, Novartis has financial assistance programs, and Medicaid covers it in most states. Spinraza and Evrysdi also have patient assistance programs. Specialty pharmacies and patient advocates can navigate access. SMA News Today (smanewstoday.com) maintains updated assistance program information.

🫁
5

Set up multidisciplinary care from day one

SMA requires a team: pulmonologist (respiratory monitoring is critical for types 1-2), physical therapist, occupational therapist, nutritionist, orthopedic specialist, and speech therapist. Annual multidisciplinary clinic visits at SMA care centers are the standard of care. Don't wait until problems arise to set these up.

🔔 FREE ALERTS + PERSONALIZED UPDATES

Get SMA Research Updates — Personalized to Your Situation

Weekly updates from NIH, FDA, and ClinicalTrials.gov. Tell us a little about your situation and we'll filter what's most relevant for you. Free. No spam. Unsubscribe anytime.

Only email is required. By subscribing you agree to receive updates from My Sugar Pill. We never sell your data. Privacy policy.

Community Feed

What patients and caregivers are saying about SMA

View All →
⏳
Loading community posts…
Have something to share?

Join the SMA community discussion on /pulse — share your experience, ask questions, or post research you've found.

Go to Pulse →

📰 Latest SMA Research & News

🧠

Research updates coming soon

Our pipeline pulls daily from NIH, CDC, and FDA. Check back tomorrow for the latest SMA research.

About this content

Sourced from U.S. government health agencies (NIH, CDC, FDA) and ClinicalTrials.gov. Summaries written in plain English for a 55+ audience. Always consult your doctor before making healthcare decisions. My Sugar Pill does not provide medical advice.

About My Sugar Pill · No sponsored content · No data selling · Free, always.

❓ Frequently Asked Questions About SMA

Answers in plain English — no jargon. Based on what patients, caregivers, and newly diagnosed people actually ask.